[Pharmacodynamics and results of a clinical trial of nitrogranulong, a new Soviet long-acting preparation of nitroglycerin].
In the USSR, the Research and Production Association "Vitamins" and the Department of Pharmacology, All-Union Research Institute of Medicinal Plants were the first to develop commercial processes for manufacturing trinitroglycerol microgranules on the basis of the raw material available in this country and to design the new long-acting drug Nitrogranulong. Experimental examinations revealed that Nitrogranulong showed the same bioavailability as Nitro-Mack-Retard and sustac, produced a prolonged coronarolytic effect, and caused the hemodynamic and ECG changes typical of trinitroglycerol. The agent was found to be low toxic and well tolerated in a dosage form. Clinical examination of 467 patients indicated that Nitrogranulong exhibited the same antianginal potency, but in some cases it was superior to sustac, nitrong, 2% nitroglycerin ointment, and nitrosorbide. The agent caused significantly less adverse and toxic effects. Nitrogranulong is used in medical practice to prevent anginal episodes. It is produced in tablets in two dosages (2.9 and 5.2 mg trinitroglycerol), its action duration being 7-8 hours.